

Subt. For, PTO-1449 INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Docket Number 289591.136 US1		Application Number 10/620,619	
				Applicant Nivorozhkin et al.			
				Filing Date July 17, 2003		Group Art Unit 1616 / 626	
Sheet	1	OF	7				

U.S. Patent Documents							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUB- CLASS	FILING DATE IF APPROPRIATE
YD	AA	6,277,998	8/21/2001	Ushio			
	AB	6,191,289	2/20/2001	Ushio			
	AC	5,874,593	2/23/1999	Ushio			
	AD	5,284,954	2/8/1994	Wittenberger			
	AE	6,388,088	5/14/2002	Sidduri			
	AF	5,049,572	9/17/1991	Scherrer et al.			
	AG	5,232,937	8/3/1993	Makovec et al.			
	AH	5,364,869	11/15/1994	De et al.			
	AI	5,663,357	9/2/1997	Teng et al.			
	AJ	5,976,576	11/2/1999	Makovec et al.			
	AK	6,297,261	10/2/2001	Christopherson et al.			
	AL	6,417,393	7/9/2002	Christopherson et al.			
	AM	2002/00322 10	8/1/2002	Pinto et al.			
	AN	2002/00322 10	3/14/2002	Dahl et al.			
	AO	2002/00379 05	3/28/2002	Dahl et al.			
	AP	6,696,479	2/24/2004	Van Der Schaaf et al.			
	AQ	6,706,749	3/16/2004	Dahl et al.			

Foreign Patent Documents							
EXAMINER INITIAL		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION YES NO
YD	AR	WO 02/00647	1/03/2002	PCT			
	AS	WO 01/85705	11/15/200	PCT			
	AT	0638553	7/26/1994	Europe			
	AU	WO 90/09989	9/7/1990	PCT			
	AV	WO 93/16053	8/19/1993	PCT			

EXAMINER T. A. Solpla	DATE CONSIDERED 11-22-04
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

Subt. For, PTO-1449 INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Docket Number		Application Number	
				289591.136 US1		10/620,619	
				Applicant Nivorozhkin et al.			
Sheet 2 OF 7				Filing Date		Group Art Unit	
				July 17, 2003		1616 / 626	

YD	AW	WO 98/58522	12/23/199	PCT				
	AX	WO 99/24442	5/20/1999	PCT				
	AY	WO 00/16798	3/30/2000	PCT				
	AZ	WO 00/24707	5/4/2000	PCT				
	BA	WO 00/28979	5/25/2000	PCT				
	BB	WO 00/64888	11/2/2000	PCT				
	BC	WO 01/66098	9/13/2001	PCT				
	BD	WO 02/00647	1/3/2002	PCT				

Other Documents (Including Author, Title, Date, Pertinent Pages, etc.)

YD	BE	Oda et al., Oxygen radicals in influenza-induced pathogenesis and treatment with pyran polymer-conjugated SOD, Science. 1989 May 26;244(4907):974-6.
	BF	Tan et al., Xanthine oxidase activity in the circulation of rats following hemorrhagic shock, Free Radic Biol Med. 1993 Oct;15(4):407-14.
	BG	McCord J.M., Oxygen-derived free radicals in postischemic tissue injury, N Engl J Med. 1985 Jan 17;312(3):159-63.
	BH	Miesel et al., "Effects of allopurinol on in vivo suppression of arthritis in mice and ex vivo modulation of phagocytic production of oxygen radicals in whole human blood", Inflammation. 1994 Dec;18(6):597-612.
	BI	Engerson et al., Conversion of xanthine dehydrogenase to oxidase in ischemic rat tissues, J Clin Invest. 1987 Jun;79(6):1564-70.
	BJ	Akaike et al., Dependence on O ₂ - generation by xanthine oxidase of pathogenesis of influenza virus infection in mice, J Clin Invest. 1990 Mar;85(3):739-45.
	BK	Kelai et al., Plasma hypoxanthine and exercise. Am Rev Respir Dis. 1987 Jul;136(1):98-101.
	BL	Mohacsi et al., Neutrophils obtained from obliterative atherosclerotic patients exhibit enhanced resting respiratory burst and increased degranulation in response to various stimuli, Biochim Biophys Acta. 1996 Aug 23;1316(3):210-6.
	BM	Friedl et al., Ischemia-reperfusion in humans. Appearance of xanthine oxidase activity. Am J Pathol. 1990 Mar;136(3):491-5.
	BN	Friedl et al., Roles of histamine, complement and xanthine oxidase in thermal injury of skin. Am J Pathol. 1989 Jul;135(1):203-17.

EXAMINER T. A. Solola	DATE CONSIDERED 11-22-04
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

US1DOCS 4816279v1

Subt. For, PTO-1449				Docket Number 289591.136 US1		Application Number 10/620,619	
INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Applicant Nivorozhkin et al.			
				Filing Date July 17, 2003		Group Art Unit 1618/1626	
Sheet	3	OF	7				

YD	BO	Parks et al., Role of oxygen free radicals in shock, ischemia, and organ preservation. Surgery. 1983 Sep;94(3):428-32.
	BP	Demling et al., Lung oxidant changes after zymosan peritonitis: relationship between physiologic and biochemical changes. Am Rev Respir Dis. 1992 Nov;146(5 Pt 1):1272-8.
	BQ	Chambers et al., Xanthine oxidase as a source of free radical damage in myocardial ischemia. J Mol Cell Cardiol. 1985 Feb;17(2):145-52.
	BR	Deitch et al., Hemorrhagic shock-induced bacterial translocation is reduced by xanthine oxidase inhibition or inactivation. Surgery. 1988 Aug;104(2):191-8.
	BS	Mayumi et al., Zonal heterogeneity of hepatic injury following shock/resuscitation: relationship of xanthine oxidase activity to localization of neutrophil accumulation and central lobular necrosis. Shock. 1996 May;5(5):324-32.
	BT	Flynn et al., Allopurinol plus standard resuscitation preserves hepatic blood flow and function following hemorrhagic shock. J Trauma. 1994 Dec;37(6):956-61.
	BU	Zollei, I., Experimental study of hypovolaemic shock-induced gastric mucosal lesions in the rat. Ann Acad Med Singapore. 1999 Jan;28(1):85-9.
	BV	Flynn et al., Allopurinol plus standard resuscitation preserves hepatic blood flow and function following hemorrhagic shock. J Trauma. 1994 Dec;37(6):956-61.
	BW	Modelska et al., Inhibition of beta-adrenergic-dependent alveolar epithelial clearance by oxidant mechanisms after hemorrhagic shock. Am J Physiol. 1999 May;276(5 Pt 1):L844-57.
	BX	Flynn et al., Xanthine oxidase inhibition prevents mesenteric blood flow deficits after resuscitated hemorrhagic shock by preserving endothelial function. J Surg Res. 1997 Mar;68(2):175-80.
	BY	Mannion et al., Role of xanthine oxidase inhibition in survival from hemorrhagic shock. Circ Shock. 1994 Jan;42(1):39-43.
	BZ	Cunningham and Keaveny, Effect of a xanthine oxidase inhibitor on adenine nucleotide degradation in hemorrhagic shock. Eur Surg Res. 1978;10(5):305-13.
	CA	Youn et al., Oxidants and the pathophysiology of burn and smoke inhalation injury. Free Radic Biol Med. 1992;12(5):409-15.
	CB	Deitch et al., A study of the relationship among survival, gut-origin sepsis, and bacterial translocation in a model of systemic inflammation. J Trauma. 1992 Feb;32(2):141-7.
	CC	Anderson et al., Hypovolemic shock promotes neutrophil sequestration in lungs by a xanthine oxidase-related mechanism. J Appl Physiol. 1991 Nov;71(5):1862-5.

EXAMINER

T. A. Solola

DATE CONSIDERED

11-22-04

EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.

USIDOC5 4816279v1

Subt. For, PTO-1449 INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Docket Number 289591.136 US1		Application Number 10/620,619	
				Applicant Nivorozhkin et al.			
				Filing Date July 17, 2003		Group Art Unit 1616 / 626	
Sheet	4	OF	7				

40	CD	Pogetti et al., Simultaneous liver and lung injury following gut ischemia is mediated by xanthine oxidase. J Trauma. 1992 Jun;32(6):723-7; discussion 727-8.
	CE	Nielsen et al., Xanthine oxidase inactivation attenuates postocclusion shock after descending thoracic aorta occlusion and reperfusion in rabbits. J Thorac Cardiovasc Surg. 1995 Sep;110(3):715-22.
	CF	Schwartz et al., Xanthine oxidase-derived oxygen radicals increase lung cytokine expression in mice subjected to hemorrhagic shock. Am J Respir Cell Mol Biol. 1995 Apr;12(4):434-40.
	CG	Crowell et al., Effect of allopurinol on hemorrhagic shock. Am J Physiol. 1969 Apr;216(4):744-8.
	CH	Linder et al., Cellular expression of xanthine oxidoreductase protein in normal human tissues. Lab Invest. 1999 Aug;79(8):967-74.
	CI	Saksela et al., Xanthine oxidoreductase gene expression and enzyme activity in developing human tissues. Biol Neonate. 1998 Oct;74(4):274-80.
	CJ	Battelli et al., Determination of xanthine oxidase in human serum by a competitive enzyme-linked immunosorbent assay (ELISA). Clin Chim Acta. 1999 Mar;281(1-2):147-58.
	CK	Houston et al., Binding of xanthine oxidase to vascular endothelium. Kinetic characterization and oxidative impairment of nitric oxide-dependent signaling. J Biol Chem. 1999 Feb 19;274(8):4985-94.
	CL	Fox et al., Immunohistochemical localization of xanthine oxidase in human retina. Free Radic Biol Med. 1998 Apr;24(6):900-5.
	CM	Rouquette et al., Xanthine oxidoreductase is asymmetrically localised on the outer surface of human endothelial and epithelial cells in culture. FEBS Lett. 1998 Apr 24;426(3):397-401.
	CN	Cardillo et al., Xanthine oxidase inhibition with oxypurinol improves endothelial vasodilator function in hypercholesterolemic but not in hypertensive patients. Hypertension. 1997 Jul;30(1 Pt 1):57-63.
	CO	Page et al., Xanthine oxidoreductase in human mammary epithelial cells: activation in response to inflammatory cytokines. Biochim Biophys Acta. 1998 Jul 23;1381(2):191-202.

EXAMINER T. A. Solola	DATE CONSIDERED 11-22-04
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

US1DOCS 4816279v1

Subt. For, PTO-1449				Docket Number 289591.136 US1		Application Number 10/620,619	
INFORMATION DISCLOSURE IN AN APPLICATION <i>(Use several sheets if necessary)</i>				Applicant Nivorozhkin et al.			
				Filing Date July 17, 2003		Group Art Unit 1616 1626	
Sheet	5	OF	7				

YD	CP	Zhang et al., Generation of nitric oxide by a nitrite reductase activity of xanthine oxidase: a potential pathway for nitric oxide formation in the absence of nitric oxide synthase activity. <i>Biochem Biophys Res Commun.</i> 1998 Aug 28;249(3):767-72.
	CQ	Trujillo et al., Xanthine oxidase-mediated decomposition of S-nitrosothiols. <i>J Biol Chem.</i> 1998 Apr 3;273(14):7828-34.
	CR	Goldfinger, S.E., Treatment of gout. <i>N Engl J Med.</i> 1971 Dec 2;285(23):1303-6.
	CS	Buchanan et al., Hypocholesterolemic 5-substituted tetrazoles. <i>J Med Chem.</i> 1969 Nov;12(6):1001-6.
	CT	Shukla and Rastogi, Studies on neuropharmacological and biochemical properties of 5-substituted tetrazoles. <i>Indian J Physiol Pharmacol.</i> 1981 Oct-Dec;25(4):369-73.
	CU	Springer et al., 1916, <i>J. Med. Chem.</i> 19, 291; U.S. Patent No.: 4,021,566
	CV	Skipper et al., Inhibition of experimental neoplasms by 4-aminopyrazolo (3, 4-d) pyrimidine. <i>Proc Soc Exp Biol Med.</i> 1955 Aug;89(4):594-6.
	CW	Demko and Sharpless, Preparation of 5-substituted 1H-tetrazoles from nitriles in water. <i>J Org Chem.</i> 2001 Nov 30;66(24):7945-50.
	CX	Butler, R.N., <i>Comprehensive Heterocyclic Chemistry</i> , Katritzky, et al., Eds., Pergamon: Oxford, U.K., 1996, Volume 4.
	CY	Isida et al., The Formation of Tin-Nitrogen Bonds. V. The Selective 1-Substitution Reaction of 5-Substituted 1-(Tri-n-butylstannyl tetrazoles) with Methyl Iodide, Methyl p-Toluenesulfonate, Dimethyl Sulfate, and Ethyl Bromoacetate. <i>Chemical Society of Japan</i> , Vol. 46, 2176-2180. (1973)
	CZ	Rosenbaum et al., 1992, "Thermolyse von 1-Thiocarbamoyl-5-phenyl-tetrazolen", <i>J. Prakt. Chem.</i> 334:283-4.
	DA	Myznikov et al., Tetrazoles XXV. Production of N-benzoyltetrazoles and their chemical characteristics. <i>J. Org. Chem. USSR</i> 1988 Dec 20, 24(7):1397-1401.
	DB	A. Konnecke et al., 1978, <i>Tetrahedron letters</i> , No. 7, 533-536.
	DC	Oshipova et al., Tetrazoles XIX. Acylation of tetrazoles under the conditions of phase-transfer catalysis. <i>J. Org. Chem. USSR</i> 1984 20(11):2248-2252.
	DD	Jursic B.S., 1993, "Acyltetrazole As an Intermediate for Preparation of Carboxylic Acid Derivatives", <i>Synthetic Communications</i> , 23(3):361-4.

EXAMINER T.A. Solola	DATE CONSIDERED 11-22-04
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

US1DOC8 4816279v1

Subt. For, PTO-1449				Docket Number 289591.136 US1		Application Number 10/620,619	
INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Applicant Nivorozhkin et al.			
				Filing Date July 17, 2003		Group Art Unit 1616-1626	
Sheet	6	OF	7				

Y0	DE	Ichibuchi et al., Synthesis and structure-activity relationships of 1-phenylpyrazoles as xanthine oxidase inhibitors. <i>Bioorg. Med. Chem. Lett.</i> 2001 <u>11</u> (7):879-882.
	DF	Nagamatsu et al., Novel xanthine oxidase inhibitor studies. Part 2. Synthesis and xanthine oxidase inhibitory activities of 2-substituted 6-alkyl-indenehydrazino- or 6-arylmethylindenenehydrazino-7H-purines and 3- and/or 5-substituted 9H-1,2,4-triazolo[3,4-i]purines. <i>J. Chem. Soc. Perkin Trans. 1</i> 1999 <u>3</u> 117-3125.
	DG	Baldwin et al., 1975, 4-Trifluoromethylimidazoles and 5-(4-Pyridyl)-1,2,4-triazoles, New Classes of Xanthine Oxidase Inhibitors: <i>J. Of Med. Chemistry</i> , v. 18 no. 9.
	DH	<i>J. of Org. Chem of the USSR, Russian Original Vol. 20., no. 5, Part 2, May 1984.</i>
	DI	Czuczwar et al., A potential anti-asthmatic drug, CR 2039, enhances the anticonvulsive activity of some antiepileptic drugs against pentetrazol in mice. <i>Eur Neuropsychopharmacol.</i> 1998 <u>Aug</u> ;8(3):233-8.
	DJ	Czuczwar et al., Influence of a potential anti-asthmatic drug, CR 2039, upon the anticonvulsive activity of conventional antiepileptics against maximal electroshock-induced seizures in mice. <i>J Neural Transm.</i> 1996;103(12):1371-9.
	DK	Makovec F., Antiallergic and cytoprotective activity of new N-phenylbenzamido acid derivatives. <i>J Med Chem.</i> 1992 <u>Oct</u> 2;35(20):3633-40.
	DL	Revel et al., CR 2039, a new bis-(1H-tetrazol-5-yl)phenylbenzamide derivative with potential for the topical treatment of asthma. <i>Eur J Pharmacol.</i> 1992 <u>Dec</u> 8;229(1):45-53.
	DM	Revel et al., Pharmacological profile of CR 2039 (Dizolast) a new agent for the treatment of allergic diseases, <i>Life Sciences</i> , 229:273-7. 1992.
	DN	Persiani et al., Pharmacokinetics of andolast after administration of single escalating doses by inhalation in mild asthmatic patients. <i>Biopharm Drug Dispos.</i> 2001 <u>Mar</u> ;22(2):73-81.
	DO	Blake et al., 1997, "Xanthine Oxidase: Four Roles for the Enzyme in Rheumatoid Pathology" <i>Biochemical Society Transactions</i> , 25:1-7
	DP	Boros et al., 1989, "Oxygen Free Radical-Induced Histamine Release During Intestinal Ischemia and Reperfusion", <i>Eur. Surg. Res.</i> 21:297-304
	DQ	Brown et al., 1988, "Xanthine Oxidase Produces Hydrogen Peroxide which Contributes to Reperfusion Injury of Ischemic, Isolated, Perfused Rat Hearts", <i>J. Clin. Invest.</i> 81:1297-301.
✓	DR	Deliconstantinos et al., 1996, "Alterations of Nitric Oxide Synthase and Xanthine Oxidase Activities of Human Keratinocytes by Ultraviolet B Radiation", <i>Biochem. Pharm.</i> 51:1727-1738.

EXAMINER <i>T. A. Solola</i>	DATE CONSIDERED <i>11-22-04</i>
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609: Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

US1DOCS 4816279v1

Subl. For, PTO-1449 INFORMATION DISCLOSURE IN AN APPLICATION (Use several sheets if necessary)				Docket Number 289591.136 US1		Application Number 10/620,619	
				Applicant Nivorozhkin et al.			
				Filing Date July 17, 2003		Group Art Unit 1616 1626	
Sheet	7	OF	7				

✓0	DS	Harrison, R., 1997, "Human Xanthine oxidoreductase: In Search of a Function", Biochemical Society Transactions 25: 1-7
↓	DT	Vorbach et al., The housekeeping gene xanthine oxidoreductase is necessary for milk fat droplet enveloping and secretion: gene sharing in the lactating mammary gland. <i>Genes Dev.</i> 2002 Dec 15;16(24):3223-35.

EXAMINER T. A. Solola	DATE CONSIDERED 11-22-04
EXAMINER: Initial if citation is considered, whether or not citation is in conformance with MPEP § 609; Draw Line through citation if not conformance and not considered. Include copy with next communication to applicant.	

US1DOCS 4816279v1